Protagonist Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Protagonist Therapeutics

15/03/2023 20:39

* Protagonist Therapeutics Inc  PTGX.OQ  reported a
quarterly
adjusted loss of 69 cents​​ per share for the quarter ended in
December. The mean expectation of six analysts for the quarter
was for a loss of 64 cents per share.
    * Reported revenue was zero​; analysts expected $5.00
million. 
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Protagonist Therapeutics Inc shares had risen by 131.7%
this
quarter.
    * The company reported a quarterly loss of $34.19 million.
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $33.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 15 at 08:39 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.64          -0.69          Missed
 Sep. 30 2022      -0.87          -0.64          Beat
 Jun. 30 2022      -0.93          -0.84          Beat
 Mar. 31 2022      -0.63          -0.43          Beat